Amphetamine Anorectic Drug Class List

Drugs in Drug Class: Amphetamine Anorectic

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hikma	METHAMPHETAMINE HYDROCHLORIDE	methamphetamine hydrochloride	TABLET;ORAL	203846-001	Nov 17, 2015	AA	RX	No	No
Dr Reddys Labs Sa	METHAMPHETAMINE HYDROCHLORIDE	methamphetamine hydrochloride	TABLET;ORAL	091189-001	Apr 21, 2010	AA	RX	No	No

Amphetamine Anorectic Market Dynamics and Patent Landscape

Last updated: July 31, 2026

Amphetamine anorectics are an old, largely generic drug class used for short-term obesity treatment. The principal U.S. products are phentermine, diethylpropion, benzphetamine, and phendimetrazine. Their core composition-of-matter patents expired long ago, leaving limited protection for the standalone drugs. Commercial value now depends on manufacturing scale, controlled-substance distribution, formulation differentiation, regulatory compliance, and combination products such as Qsymia, which contains phentermine and extended-release topiramate.

The class faces structural pressure from GLP-1 and GIP/GLP-1 therapies, including Wegovy, Zepbound, and Saxenda. Amphetamine anorectics remain materially cheaper and widely available through generic channels, but they have narrower labeled treatment durations, stimulant-related safety restrictions, and limited reimbursement leverage.

What drugs are included in the amphetamine anorectic class?

Amphetamine anorectics are sympathomimetic amines that reduce appetite through central nervous system stimulation. The principal FDA-approved U.S. drugs are listed below.

Active ingredient	Representative U.S. products	Common dosage forms	FDA status	DEA schedule
Phentermine	Adipex-P, Lomaira, generic phentermine	Tablets, capsules	Approved for short-term obesity treatment	Schedule IV
Diethylpropion	Tenuate, generic diethylpropion	Immediate-release and extended-release tablets	Approved for short-term obesity treatment	Schedule IV
Benzphetamine	Didrex, generic benzphetamine	Tablets	Approved for short-term obesity treatment	Schedule III
Phendimetrazine	Bontril, generic phendimetrazine	Tablets, extended-release capsules	Approved for short-term obesity treatment	Schedule III
Phentermine/topiramate extended release	Qsymia	Extended-release capsules	Approved for chronic weight management	Schedule IV because of phentermine

Amphetamine and methamphetamine are not approved as general obesity drugs. Dexfenfluramine was withdrawn from the U.S. market in 1997 after cardiovascular safety concerns. Fenfluramine was later redeveloped as Fintepla for Dravet syndrome and Lennox-Gastaut syndrome, not obesity.

When do amphetamine anorectics lose exclusivity?

The standalone amphetamine anorectics lost meaningful exclusivity decades ago. Current U.S. products are predominantly generic or authorized-generic products.

Drug	Originator approval period	Current patent position	Generic competition
Phentermine	1950s	Foundational patents expired	Extensive
Diethylpropion	1960s	Foundational patents expired	Available, but fewer suppliers than phentermine
Benzphetamine	1970s	Foundational patents expired	Limited but established
Phendimetrazine	1950s-1960s	Foundational patents expired	Available through multiple suppliers
Qsymia	2012	Combination and formulation patents have provided later protection	Generic-entry risk depends on Orange Book patents and Paragraph IV activity

For the individual active ingredients, there is no credible standalone patent-based exclusivity runway in the U.S. A manufacturer cannot normally block generic competition through the old compound patents. Any residual protection would have to arise from a particular formulation, manufacturing process, device, method of treatment, or combination product.

What patents protect phentermine and other generic anorectics?

Phentermine patent landscape

Phentermine’s commercial patent estate is effectively expired. Current market barriers are operational rather than patent-based. They include:

• Controlled-substance registration and quota management.
• State prescribing and dispensing restrictions.
• FDA current good manufacturing practice compliance.
• Active pharmaceutical ingredient sourcing.
• Product-quality and supply continuity requirements.
• Pharmacy-network access.
• Brand recognition for products such as Adipex-P and Lomaira.

Phentermine is sold in several strengths and dosage forms, including immediate-release tablets and capsules. Lomaira’s lower-dose tablet presentation creates a product-level distinction, but it does not create broad molecule exclusivity.

Diethylpropion, benzphetamine, and phendimetrazine patents

The principal patents covering these older active ingredients and their conventional oral dosage forms have expired. Their patent estates do not materially restrict generic entry.

The commercial position is more fragmented than for phentermine. Generic supply has historically been narrower, and some products have experienced intermittent availability. That can support temporary price increases, but shortages do not create durable exclusivity.

Combination and modified-release patents

The most important surviving patent activity in the class concerns products that combine an amphetamine anorectic with another active ingredient or use controlled-release technology. Qsymia is the leading example.

Qsymia combines immediate-release phentermine with extended-release topiramate. Its intellectual-property position is materially stronger than the position of generic phentermine because the product depends on:

• A specific active-ingredient combination.
• A defined dose range.
• Extended-release delivery of topiramate.
• A controlled titration and maintenance regimen.
• Risk-management procedures related to pregnancy and fetal toxicity.

The relevant patents should be assessed through the current FDA Orange Book listing and USPTO records. Patent status can change through terminal disclaimers, patent-term adjustments, reexamination, disclaimer filings, and litigation settlements. A historical patent list should not be treated as a current freedom-to-operate opinion.

What is the Orange Book status of Qsymia?

Qsymia is the main patent-protected commercial product associated with the amphetamine anorectic class. Its Orange Book position is more significant than the position of standalone phentermine products.

The product was approved by FDA in July 2012 for chronic weight management in adults and, later, in adolescents meeting specified body-mass-index criteria. Vivus developed Qsymia; the product and related rights have subsequently been subject to corporate ownership and commercialization changes.

Qsymia’s patents have covered combination treatment and extended-release dosage forms. The commercial consequence is that a generic applicant must address listed patents through one of four certifications:

1. Paragraph I, stating that no patent information is listed.
2. Paragraph II, stating that the listed patent has expired.
3. Paragraph III, stating that the applicant will wait until patent expiration.
4. Paragraph IV, asserting that the listed patent is invalid, unenforceable, or not infringed.

A Paragraph IV certification can trigger patent litigation under the Hatch-Waxman Act. The first sufficiently complete Paragraph IV filer may qualify for 180 days of generic exclusivity, although eligibility depends on the statutory requirements and the regulatory history of the application.

Which companies are challenging amphetamine anorectic patents?

Standalone generic phentermine, diethylpropion, benzphetamine, and phendimetrazine products are already commercial. Their market does not depend on active patent challenges.

The principal competitive question concerns generic Qsymia. Potential applicants must address the Orange Book patents listed for the reference product. A generic launch could occur through:

• A final court decision that listed patents are invalid or not infringed.
• A settlement permitting an agreed launch date.
• Patent expiration.
• A finding that a patent is not eligible for listing or does not block the proposed product.
• A negotiated license or authorized-generic arrangement.

Public litigation records and FDA regulatory records should be reviewed together. A patent case dismissal alone does not establish unrestricted market entry, because a settlement may contain confidential or nonpublic commercial terms and because other listed patents may remain.

What patent litigation affects Qsymia and generic entry?

Qsymia faces the standard patent risks associated with a branded combination drug:

• Invalidity challenges to obviousness, written description, enablement, or anticipation.
• Non-infringement arguments based on dose, release profile, or formulation differences.
• Orange Book listing disputes.
• Section viii carve-outs for methods of use.
• Settlement agreements that delay entry without resolving every patent claim.
• Manufacturing or formulation changes that create separate infringement questions.

For investors and licensing teams, the relevant metric is not the number of Qsymia patents alone. The stronger question is whether at least one enforceable patent covers the commercially relevant generic product through the expected launch period. A broad composition patent generally creates more leverage than a narrow method-of-use patent, while a formulation patent may be commercially important if the reference product depends on a specific release profile.

How strong is the patent estate for amphetamine anorectics?

Product category	Composition-of-matter strength	Formulation strength	Method-of-use strength	Generic-entry barrier
Generic phentermine	None of practical commercial value	Low	Low	Low
Generic diethylpropion	None of practical commercial value	Low	Low	Low
Generic benzphetamine	None of practical commercial value	Low	Low	Low
Generic phendimetrazine	None of practical commercial value	Low	Low	Low
Qsymia	Combination-specific rather than phentermine-specific	Moderate to high, depending on patent scope	Moderate	Moderate
New stimulant combination	Potentially high if newly claimed	Potentially high	Potentially high	Depends on prosecution and litigation

The class has weak patent durability because the leading molecules are old, inexpensive, and chemically simple. Product developers seeking new protection would need to differentiate through delivery technology, combination therapy, abuse-deterrent design, pediatric dosing, or a new indication.

What formulations are protected by amphetamine anorectic patents?

Most generic products use conventional immediate-release oral dosage forms. Formulation protection is therefore limited.

Commercially relevant formulation opportunities include:

• Extended-release phentermine.
• Abuse-deterrent tablets or capsules.
• Lower-dose titration products.
• Fixed-dose combinations.
• Modified-release multiparticulate systems.
• Orally disintegrating tablets.
• Pediatric formulations.
• Formulations that reduce peak plasma concentrations.
• Combination products with metabolic, endocrine, or central nervous system agents.

Formulation patents must satisfy enablement and written-description requirements across the claimed dose and release ranges. A narrow dissolution profile can provide enforceable protection, but it can also be designed around by a competing manufacturer.

What is the FDA regulatory status of amphetamine anorectics?

FDA labels generally position phentermine, diethylpropion, benzphetamine, and phendimetrazine as short-term adjuncts to caloric restriction and behavioral modification in patients with an initial body mass index meeting labeled criteria. Their approval language differs from the chronic-use labeling of modern incretin therapies.

Qsymia is approved for chronic weight management in combination with a reduced-calorie diet and increased physical activity. Its labeling includes a Risk Evaluation and Mitigation Strategy related to embryo-fetal toxicity associated with topiramate. Women of reproductive potential must follow specified pregnancy-prevention and testing requirements. The product also carries stimulant-related warnings, including heart-rate effects, mood effects, insomnia, and potential abuse or dependence concerns. (FDA, 2024a; FDA, 2024b)

The regulatory distinction is commercially important. A generic short-term anorectic cannot automatically substitute for a chronic-use obesity medicine in payer policies, clinical guidelines, or treatment pathways.

What generic launch risks exist for amphetamine anorectics?

For standalone products, launch risk is low from a patent perspective but higher from a supply-chain and compliance perspective.

Manufacturing and supply barriers

Manufacturers must manage:

• Schedule III or IV controlled-substance obligations.
• DEA manufacturing quotas.
• API supplier qualification.
• Batch-release testing.
• Diversion controls.
• State-level prescribing rules.
• Inspection and warning-letter exposure.
• Pharmacy and wholesaler allocation practices.

These factors can make an old generic commercially difficult even when no patent blocks entry. A company may have FDA approval but lack sufficient quota, API, or distribution access to achieve scale.

Qsymia launch scenarios

A generic Qsymia launch would face a different risk profile:

Scenario	Commercial effect
Entry after all relevant patents expire	Standard generic price erosion
Early entry under a settlement	Potentially controlled competition and negotiated economics
Paragraph IV victory	Accelerated erosion of branded sales
Authorized generic launch	Lower branded revenue but possible retained supply-chain economics
Formulation workaround	Narrower competitive product with possible substitutability limits
Patent survival through expected launch date	Continued Qsymia protection

How does amphetamine anorectic market demand compare with GLP-1 drugs?

Amphetamine anorectics compete primarily on price, speed of prescribing, and availability. GLP-1 and GIP/GLP-1 products compete on magnitude and durability of weight loss, cardiometabolic outcomes, chronic-use evidence, and payer interest.

Factor	Amphetamine anorectics	GLP-1/GIP therapies
Typical U.S. status	Mostly generic	Branded and patent-protected
Cost	Low for generic products	High before rebates
Treatment duration	Often short-term for legacy products	Chronic
Weight-loss profile	Generally lower and less durable	Higher in pivotal trials
Controlled-substance burden	Present	Generally absent
Patent exposure	Minimal for old molecules	High
Supply risk	DEA quotas and generic manufacturing	API, device, and manufacturing capacity
Reimbursement leverage	Limited	Variable but expanding for selected indications

The class remains commercially relevant where patients seek low-cost therapy, where insurance excludes newer obesity products, or where prescribers use phentermine within local practice standards. Its long-term market share is constrained by safety, labeling, and the clinical performance of newer therapies.

What revenue exposure exists for manufacturers?

Revenue exposure is asymmetric.

Generic manufacturers have low per-unit pricing, but they can earn attractive returns during supply disruptions or when a small number of approved suppliers serve a market. The principal risks are price competition, FDA compliance costs, controlled-substance restrictions, and abrupt changes in wholesaler demand.

The branded exposure is concentrated in Qsymia and any future proprietary combination. Qsymia revenue is vulnerable to:

• Generic entry.
• Reimbursement pressure.
• Competition from semaglutide and tirzepatide.
• Safety-driven prescribing restrictions.
• Patient switching to chronic incretin therapy.
• Reduced use of phentermine-containing products as newer drugs become more accessible.

Because public company reporting may aggregate Qsymia with other products or disclose net sales without product-level detail, revenue analysis should reconcile company filings, product-level prescription data, FDA approvals, and payer coverage information.

What geographic patent coverage applies to amphetamine anorectics?

The old molecules are broadly off-patent in the United States and major European markets. Geographic barriers now arise mainly from regulatory controls, national scheduling systems, and marketing authorizations.

Qsymia-related patent coverage may differ by jurisdiction. A company evaluating international entry should separately review:

• National patent registers.
• Patent-term adjustments and supplementary protection mechanisms.
• Local combination-product claims.
• Regulatory data exclusivity.
• National controlled-substance rules.
• Pricing and reimbursement approvals.
• Import and API restrictions.

U.S. freedom to operate does not establish freedom to operate in Europe, Canada, Japan, China, or other markets.

What licensing deals affect the amphetamine anorectic market?

Licensing value is concentrated in proprietary combinations and delivery systems, not in generic phentermine or the older anorectics. A licensor may seek rights in:

• Fixed-dose combinations.
• Extended-release technology.
• Abuse-deterrent formulations.
• Pediatric or adolescent indications.
• Digital adherence and monitoring systems.
• Regional commercialization rights.
• Authorized-generic supply arrangements.

A meaningful diligence review should examine ownership of formulation patents, regulatory exclusivity, milestone obligations, territory restrictions, manufacturing rights, and termination provisions. Licensing a generic active ingredient without differentiated IP generally has limited strategic value.

Key Takeaways

• Phentermine, diethylpropion, benzphetamine, and phendimetrazine are substantially off-patent in their conventional forms.
• The principal barriers for generic manufacturers are controlled-substance compliance, DEA quotas, API supply, and distribution.
• Qsymia is the central patent-protected product in the class because it combines phentermine with extended-release topiramate.
• Orange Book patents, Paragraph IV certifications, settlements, and formulation design-arounds determine Qsymia’s generic-entry timing.
• Legacy anorectics compete on price and access, while GLP-1 and GIP/GLP-1 drugs compete on efficacy, chronic-use evidence, and outcomes.
• New commercial value requires differentiated formulations, combinations, delivery systems, or indications rather than another conventional oral stimulant product.

FAQs

Is phentermine still patent-protected?

No. The original phentermine molecule and conventional dosage forms are long off-patent. Current products compete primarily as generics or branded generics.

Can a generic manufacturer launch Qsymia without infringing phentermine patents?

Potentially, but Qsymia-related patents may cover the combination, dosage regimen, or extended-release formulation. The applicant must assess the current Orange Book listings and certify under Hatch-Waxman.

Are amphetamine anorectics eligible for chronic obesity treatment?

Most legacy products are labeled for short-term use. Qsymia is approved for chronic weight management, subject to its labeling, contraindications, and risk-management requirements.

Do amphetamine anorectics have biosimilar competition?

No. These are small-molecule drugs, not biologics. Competition occurs through ANDAs and generic products, not biosimilar applications.

What is the main investment risk for a new amphetamine anorectic product?

The main risks are weak molecule-level patent protection, competition from low-cost generics, controlled-substance regulation, and displacement by branded incretin-based obesity therapies.

References

1. Drug Enforcement Administration. (2024). Controlled substances schedules. U.S. Department of Justice. https://www.dea.gov/drug-information/drug-scheduling

2. U.S. Food and Drug Administration. (2024a). Adipex-P (phentermine hydrochloride) prescribing information. https://www.accessdata.fda.gov

3. U.S. Food and Drug Administration. (2024b). Qsymia (phentermine and topiramate extended-release) prescribing information. https://www.accessdata.fda.gov

4. U.S. Food and Drug Administration. (2024c). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

5. U.S. Food and Drug Administration. (2024d). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

6. U.S. Patent and Trademark Office. (2024). Patent Center. https://patentcenter.uspto.gov

7. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.